Oxidative stress and autophagy in cardiac disease, neurological disorders, aging and cancer

Eric E. Essick and Flora Sam

1Whitaker Cardiovascular Institute; 2Cardiovascular Section and Evans Department of Medicine; Boston University School of Medicine; Boston, MA USA

Key words: autophagy, reactive oxygen species, oxidative stress, ischemia/reperfusion injury, pathogenesis

Autophagy is a catalytic process of the bulk degradation of long-lived cellular components, ultimately resulting in lysosomal digestion within mature cytoplasmic compartments known as autophagolysosomes. Autophagy serves many functions in the cell, including maintaining cellular homeostasis, a means of cell survival during stress (e.g., nutrient deprivation or starvation) or conversely as a mechanism for cell death. Increased reactive oxygen species (ROS) production and the resulting oxidative cell stress that occurs in many disease states has been shown to induce autophagy. The following review focuses on the roles that autophagy plays in response to the ROS generated in several diseases.

Introduction

While production of reactive oxygen species (ROS) is a consequence of basal cellular respiration, increased ROS production is associated with several pathological conditions (i.e., hypoxia, ischemia) in many cellular systems. ROS can alter gene/protein expression by acting as second messenger molecules that can influence intercellular signaling cascades, ultimately affecting cell phenotype and function. Additionally, ROS can directly oxidize cellular components (i.e., lipids, DNA, proteins, mitochondrial components) leading to detrimental effects on the cell and contributing to disease progression. ROS have been ascribed as positive regulators of autophagy, a process of bulk degradation of organelles and proteins, in a multitude of cell systems, which may contribute to the ultimate fate of the cell, be it cell survival or death. This review highlights the roles of autophagy in response to ROS and increased conditions of oxidative stress and the relationship to several disease states (i.e., cancer, aging, neurological and vascular disorders).

Autophagy

Autophagy is a tightly regulated and evolutionary conserved process, and includes three main forms: chaperone-mediated autophagy (CMA), microautophagy and macroautophagy. CMA has been described exclusively in mammals and evolutionary data indicates it developed in response to the evolving needs of the species. CMA requires the complete unfolding of the autophagic materials prior to entry into lysosomes, and allows for individual proteins to be singled out and degraded. In contrast, both micro and macroautophagy sequester large amounts of cytosolic components for bulk degradation. Furthermore, microautophagy is characterized by the direct uptake of these cytosolic constituents through an invagination of the lysosomal membrane. This review focuses on macroautophagy (hereafter referred to as simply “autophagy”), which is a more common yet more complex mechanism for protein and organelle degradation in lysosomal vacuoles. During this catabolic process, long-lived organelles and cytoplasmic proteins are initially engulfed into polymembrane vesicles, known as phagophores. The edges of these phagophores expand in a process of vesicle elongation, and fuse to form the mature autophagosome. These autophagosomes subsequently fuse with intercellular lysosomes, forming autophagolysosomes, inside of which the damaged sequestered material is degraded by lysosomal hydrolases.

Regulation of Autophagosome Formation

The formation of the autophagosome in mammalian cells involves autophagy-related proteins (ATG), which are tightly regulated, most notably downstream of mammalian target of rapamycin (mTOR) Ser/Thr kinase. Autophagosome formation is inhibited when activated mTOR phosphorylates ATG13, preventing this protein from forming a complex with ATG1. This results in the inhibition of ATG1 kinase, which is essential for autophagic induction. During the autophagic-initiation step, dephosphorylation and inactivation of mTOR allows for the association of ATG13 and ATG1, thereby activating the ATG1 kinase activity and thus initiating autophagy (Fig. 1A). Isolation membrane elongation involves two highly-conserved ubiquitin-like conjugation complexes in eukaryotes, including the ATG12-ATG5 complex, and the microtubule-associated protein 1 light chain 3 (yeast ATG8 mammalian homologue)—phosphatidylethanolamine (LC3-PE). Facilitated by ATG7 and ATG10 enzymes, the ATG12-ATG5 conjugate binds ATG16 and this resulting complex is incorporated into the outer membrane of the isolation membrane and is essential for vesicle elongation (Fig. 1B). In the LC3-PE conjugation system, full length LC3 precursor is subjected to proteolytic

---

*Correspondence to: Flora Sam; Email: flora.sam@bmc.org
Submitted: 04/04/10; Revised: 04/18/10; Accepted: 04/19/10
Previously published online: www.landesbioscience.com/journals/oximed/article/12106
Oxidative Stress Induces Autophagy

Cellular oxidative stress and increased generation of ROS have been reported to serve as important stimuli of autophagy during periods of nutrient deprivation, ischemia/reperfusion, hypoxia, and in response to cell stress. The cysteine protease ATG4 functions to cleave all homologues of ATG8 proximal to the C-terminus, priming ATG8 for subsequent conjugation to PE. In addition, the full-length LC3 precursor is cleaved by ATG4, forming LC3-I, located in the cytosol. ATG7 and ATG3 (ubiquitin-conjugating enzyme-like molecules), aid in LC3-I conjugation to PE, and this resulting complex (referred to as LC3-II), is incorporated into the autophagosome membrane aided by ATG5. The mature autophagosomes fuse with lysosomal lysosomes and are mediated by lysosomal receptor proteins (Lamp-1, Lamp-2) and Rab7. The resulting autophagolysosome is where cellular material and components are sequestered and hydrolyzed.

Figure 1. Autophagosome formation. (A) Induction: mTOR inhibition leads to downstream dephosphorylation of ATG13, allowing for its association with ATG1. This ATG13-ATG1 complex activates the kinase activity of ATG1. (B) Elongation of the isolation membrane: ATG12-ATG5, facilitated by both ATG7 and ATG10, binds ATG16 and this resulting complex becomes incorporated into the outer membrane of the isolation membrane. In addition, the full-length LC3 precursor is cleaved by ATG4, forming LC3-I, located in the cytosol. ATG7 and ATG3 (ubiquitin-conjugating enzyme-like molecules), aid in LC3-I conjugation to PE, and this resulting complex (referred to as LC3-II), is incorporated into the autophagosome membrane aided by ATG5. (C) Autophagosome maturation: The mature autophagosomes fuse with lysosomal lysosomes and are mediated by lysosomal receptor proteins (Lamp-1, Lamp-2) and Rab7. The resulting autophagolysosome is where cellular material and components are sequestered and hydrolyzed.
This leads to oxidation and consequent inhibition of ATG4, ultimately promoting ATG8-PE conjugation and enhancing autophagy.3 Although ATG4 activity is regulated by the oxidative state of the local cellular environment, the question develops as to how ATG4 is initially activated to allow for ATG8 lipidation, but then becomes inhibited to allow the lipidation of ATG8 to remain. Interestingly, the priming step of ATG8 (cleavage at the C-terminus) is not affected during initial periods of nutrient deprivation, but rather it is the increased ROS generated over prolonged cellular starvation that leads to oxidation and subsequent inhibition of ATG4 (Fig. 2).3

ROS induce autophagy through a beclin-1 dependent pathway that is associated with autophagic induced cell-death.29 Beclin-1 is negatively regulated by its interaction with the anti-apoptotic protein Bcl-2 under normal conditions.30 However, increased ROS activates the ubiquitin-proteosome system, which functions to degrade Bcl-2.31 This allows for beclin-1 activation subsequently resulting in autophagic cell death.29 Additionally, oxidized low density lipoproteins may enhance autophagy by upregulating beclin-1 gene expression.32 siRNA against beclin-1 attenuates ROS-mediated ganglioside induced autophagic cell death.33

Increased autophagy reportedly occurs with mitochondrial damage and/or failure of the mitochondria to generate adequate ATP levels (i.e., during cell starvation), thus implicating a key role for mitochondria in autophagy.34,35 Inhibition of the mitochondrial electron transport chain (mETC) results in increased ROS production that is accompanied by cell death.36 Furthermore, inhibition of mETC complex I and complex II with rotenone and trifluoroacetone respectively caused ROS-mediated autophagic-induced cell death in transformed and cancer cell lines.37

Our laboratory among others has shown that aldosterone causes a generation in ROS in cultured adult rat ventricular myocytes.38 In vivo this leads to enhanced activity associated with cardiac remodeling including hypertrophy, increased matrix metalloproteinase activity, fibrosis, as well as apoptosis.39,40 Additionally, autophagic stimulation has been linked to pathologic conditions of cardiac remodeling in response to oxidative stress, endoplasmic reticulum stress, and changes in the ubiquitin-proteosomal system.41,42 Previous unpublished data from our laboratory suggests that pathologic levels of ROS induce autophagic mediated cardiomyocyte death through an ERK-MAPK-dependent pathway. Further exploration into the exact mechanism of autophagic mediated cardiomyocyte death in response to severe oxidative stress is needed.

**Cellular Functions of Autophagy**

Autophagy serves many functions in response to various stimuli throughout a multitude of cell systems. Basal levels of autophagic degradation of longed lived cell components (i.e., organelles, cytosolic proteins) occur in nearly all cell types as a means to maintain cellular homeostasis.4 A robust enhancement of autophagy has been observed in developing mouse embryos, suggesting that this process plays an important role in development and cell differentiation.3,4,43 Additionally, autophagy rapidly increases during periods of cellular starvation as a means to generate the necessary nutrients to sustain cell survival.44 However, excessive autophagy results in degradation of essential cell constituents, ultimately resulting in a process referred to as type-II cell death.45 Determinants of whether autophagy promotes cell survival or cell death depend upon the severity and degree of stress in the cellular environment. Autophagic degradation and removal of damaged oxidized proteins in response to oxidative stress is reportedly beneficial for the cell.46,47 Conversely, severe oxidative stress and increasing amounts of ROS may activate signaling pathways that lead to autophagic-induced cell death.48

**Oxidative-Stress Induced Autophagy in Response to Disease**

Many disease states are associated with elevated levels of ROS and increased oxidative stress and range from cardiovascular-associated disorders such as heart failure and diabetes, to neurodegenerative diseases, cystic fibrosis, rheumatoid arthritis and cancer.49-55 Elevated ROS causing autophagy promotes either
cell survival or cell death, the fate of which depends upon the severity of the stress occurring with a particular disease. The following sections discuss the autophagic response to increased ROS in various disease states and pathologic conditions. Refer to Table 1 for a summary of the role of autophagy in these diseases.

(1) Autophagy in vascular disease. Autophagic activity may be rapidly increased in response to vascular stress that occurs during ischemic episodes. Autophagy was first reported in cardiomyocytes by Sybers et al. in 1975, and occurs in response to acute coronary occlusion and myocardial infarction.42,56-60

Once coronary artery flow is reestablished, it can be classified as an ischemia/reperfusion (I/R) injury. During the initial period of ischemia, formation of the enzyme xanthine oxidase (XO) occurs and hypoxanthine and xanthine, both substrates for XO, accumulate.61,62 Upon reperfusion, the reintroduction of molecular oxygen leads to XO-mediated superoxide radical (O$_2^-$) generation due to the presence of xanthine and hypoxanthine.63 During the initial period of hypoxia, a modest induction of autophagy occurs, and pharmacological inhibition of autophagy with 3-methyladenine (3-MA) decreased cardiomyocyte survival during ischemia, suggesting a cell survival role for autophagy during the initial ischemic insult.58,63 During this period, the resulting decrease in ATP generation results in the phosphorylation of AMP-activated protein kinase (AMPK), which leads to autophagosome formation through inhibition of mTOR.64,65 Ischemic insult also results in phosphorylation of heat shock protein (Hsp)20 at serine residue 16, leading to autophagosome formation through inhibition of mTOR and leads to cell death 74–75. This ultimately leads to the induction of cell death and is thus detrimental to cell function. Furthermore, AMPK activity decreases during reperfusion, thus increasing autophagic degradation of essential cell constituents resulting in death 76–78.

Table 1. Autophagy and ROS in disease states

<table>
<thead>
<tr>
<th>Disease</th>
<th>Cell/system</th>
<th>Function of autophagy</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pathologic cardiac remodeling</td>
<td>Cardiac tissue</td>
<td>Oxidative stress-mediated autophagic cell death</td>
<td>41, 42</td>
</tr>
<tr>
<td>Heart failure</td>
<td>Cardiomyocytes</td>
<td>Pathologic levels of ROS-mediated autophagic cell death</td>
<td>unpublished</td>
</tr>
<tr>
<td>Myocardial infarction/ischemia reperfusion</td>
<td>Cardiomyocytes</td>
<td>Xanthine oxidase mediated ROS generation exacerbates autophagy and leads to death</td>
<td>42, 56–60</td>
</tr>
<tr>
<td>Renal ischemia reperfusion injury</td>
<td>Renal tubule epithelial cells</td>
<td>I/R-mediated ROS generation, increases autophagy and leads to cell death</td>
<td>74, 75</td>
</tr>
<tr>
<td>Stroke, neuronal ischemic injury</td>
<td>Neuronal cells</td>
<td>I/R-mediated ROS generation, increases autophagy and leads to cell death</td>
<td>76–78</td>
</tr>
<tr>
<td>Huntington disease, Alzheimer, Parkinson</td>
<td>Neuronal cells</td>
<td>ROS generation induces pro-survival autophagic removal of harmful protein aggregates</td>
<td>82–86</td>
</tr>
<tr>
<td>Alzheimer</td>
<td>Neuronal cells</td>
<td>Excessive ROS generation leading to mitochondrial damage, increasing autophagic degradation of essential cell constituents resulting in death</td>
<td>97</td>
</tr>
<tr>
<td>Epilepsy</td>
<td>Neuronal cells</td>
<td>ROS generation mediates cystatin C-induced autophagic clearance of harmful aggregates (i.e., stefin B)</td>
<td>87, 88</td>
</tr>
<tr>
<td>Aging</td>
<td>Post-mitotic cells</td>
<td>Impairment of lysosome/autophagosome fusion and loss of autophagic function during aging leads to accumulation of ROS and damaged cell material and cell death</td>
<td>4, 105, 106, 110</td>
</tr>
<tr>
<td>Cancer/Tumor formation</td>
<td>Prostate and colorectal cancer cells</td>
<td>Reduced autophagic activity accompanied by ROS accumulation, somatic mutations and cancer pathogenesis</td>
<td>63, 121, 122</td>
</tr>
<tr>
<td>Cancer/Tumor survival</td>
<td>Pre-existing tumors/multiple myeloma cells, cervix carcinoma</td>
<td>Cell starvation and ROS triggered autophagy promotes tumor survival in nutrient deprived environments</td>
<td>135, 137–139</td>
</tr>
</tbody>
</table>

I/R injury induce ROS generation and autophagic-mediated cell death in the renal vasculature. Hypoxia induces autophagic cell death in human renal proximal tubular epithelial HK-2 cells, and autophagic inhibition prevented H$_2$O$_2$-induced cell death.73 Furthermore, overexpression of the anti-apoptotic protein Bcl-2 in mice prevented autophagosome formation in I/R-injured renal tubular cells.74 Others reported that adenoviral administration of Bcl-xl, a member of the Bcl-2 family, significantly reduced I/R-induced superoxide production and autophagy in the proximal and distal tubules of rat kidney.75 As in the myocardium, periods of intermittent reperfusion...
during prolonged ischemia protects against renal dysfunction as compared to classical I/R injury, and this involved an increase in antioxidant defense mechanisms and suppression of oxidative stress and autophagy.  

Enhanced autophagy activity is seen in ischemic events occurring in the cerebral vasculature. In the penumbra of rats exposed to cerebral ischemia there is increased beclin-1 and LC3 protein expression observed along with DNA damage in neuronal cells, suggesting cell death. Neuronal rats subjected to focal cerebral ischemia exhibited autophagosome specific LC3-II protein expression located in the periphery of neuronal lesions, indicating autophagic-mediated cell death. Post-ischemic treatment with the autophagic inhibitor 3-MA reduced the size of these lesions. Others showed that ATG7-deficient neonatal mice subjected to ischemic episodes were completely protected from neuronal death, suggesting ATG7 as a potential therapeutic target against neuronal cell death following ischemic brain injuries such as stroke. Repeated I/R in a rat spinal cord injury model resulted in enhanced immunoreactivity of LC3 and eventually neuronal death. Conversely, it has been suggested that activation of autophagy actually promotes cell survival in the initial stages of ischemic brain injury. Treatment with rapamycin, an autophagic inducer, increased beclin-1 expression, and lead to a reduction in cell death and neuronal injury in response to neonatal ischemic injury. Finally, ischemic-preconditioning lead to increased LC3-II expression in an in vitro PC12 cell model, and blockage of autophagy with 3-MA decreased cell viability, indicating that autophagy plays a neuroprotective role in ischemic preconditioning.

(2) Role of autophagy in neurodegenerative disease. Debate continues as to whether autophagy directly contributes to neurodegenerative diseases or if it serves as a prosurvival response. Once again basal autophagy may lead to the clearance and degradation of potentially harmful protein aggregates that are associated with Huntington, Parkinson, and Alzheimer diseases, therefore being important in the protective maintenance of neural cells. For instance, in a dopamine D (2) receptor knockout mouse model of Parkinson’s disease, increased oxidative stress and formation of alpha-synuclein aggregate is associated with increased autophagic activity. Confocal microscopy revealed colocalization of LC3 and stefin B aggregates, a protein linked with epileptic syndromes leading to neurodegeneration and increased oxidative stress. Cystatin C (CysC) is increased in the brain of animal models with neurodegenerative diseases and in human epileptic patients, and may have a neuroprotective role in response to oxidative stress. CysC enhances autophagic clearance of aggregates via a mTOR dependent pathway. Conversely, beclin-1 siRNA or 3-MA inhibits the neuroprotective role of CysC. ATG5 knockdown and suppression of basal autophagy caused protein aggregate accumulation in mouse neural cells and was accompanied by impaired motor function. Similarly, suppression of ATG7 in the central nervous system of mice was accompanied by impaired motor function, behavioral defects, protein inclusion body accumulation, neurodegeneration in both the cerebral and cerebellar cortices, and death. In both Drosophila and mouse models of polyglutamine diseases induction of autophagy with the use of rapamycin analogues prevents neurodegeneration. Furthermore, studies utilizing small molecular inhibitors of rapamycin induced autophagic degradation of mutant Huntington protein aggregates and protected against neurotoxicity in Huntington disease cell and Drosophila models. Finally, overexpression of ATG8a gene in aged Drosophila brains promoted resistance to oxidative stress and prevented the build up of oxidized and ubiquitinated protein aggregates while extending lifespan. These findings suggest that pharmacologic modulators of autophagy may be applied as potential therapeutic interventions against neurodegenerative diseases.

In many cases, increased oxidative stress and ROS generation are observed in neurodegenerative disorders resulting in enhanced autophagic activity beyond basal levels. Under these conditions, autophagy is no longer considered a cell-survival mechanism, but promotes type-II programmed cell death. An increased number of autophagosomes are found in the brains of patients diagnosed with Alzheimer, Huntington and Parkinson diseases. Dopamine-toxicity inhibited mTOR, leading to an increase in LC3-II expression and cell loss in SH-SY5Y neuroblastoma cells. This was prevented with the antioxidant N-acetylcysteine, suggesting that products of dopamine oxidation play a role in autophagic-induced neural cell degeneration. In Alzheimer disease, oxidative stress caused neuronal cell death by inducing autophagy of accumulated amyloid β-protein (Abeta) and subsequent permeabilization of the lysosomal membrane contributing to neuron death. Mitochondria damaged by oxidative stress in pyramidal neurons are subjected to autophagic degradation in Alzheimer disease (termed mitophagy), eventually leading to neurodegeneration. Finally, aberrant expression of protein phosphatase 2A (PP2A) is associated with the onset of a number of neural degenerative disorders. It was recently reported that neuroblastoma cells transfected with PP2A constructs have an increased susceptibility to oxidative stress mediated cell death, and inhibition of autophagy with siRNA against autophagic genes prevented this death.

Another mechanism of oxidative stress induced autophagy in neural cells involves Oxi-α, a neuroprotective protein identified in dopamine neurons. Oxi-α is downregulated during oxidative stress, thus rendering neurons susceptible to oxidative stress induced death. Under normal conditions, Oxi-α activates mTOR, and thus suppresses autophagosome formation. However, increased levels of ROS downregulates Oxi-α and leads to decreased mTOR activity, thereby increasing autophagosome formation. Furthermore, inhibition of autophagy with 3-MA protected against neuronal death under oxidative stress, confirming the involvement of autophagy in cell-death in neurodegenerative diseases.

(3) Autophagy and aging. Basal levels of oxidative stress as a result of aerobic metabolism over a lifespan will lead to alterations and damage to structures, eventually resulting in cell death. Lipofuscin and ceroid are related pigments that form in the presence of H2O2 and accumulate during aging in secondary lysosomes of post-mitotic cells. In both experimental and human models, there is an observed loss of autophagic...
function that occurs with aging and this is thought to be a major contributor to death of long-lived post-mitotic cells. As autophagic activity decreases during aging, it is unable to keep up with homeostatic maintenance of post-mitotic cells, resulting in an overload of ROS and damaged material, ultimately leading to cell death. Mitochondria obtained from ATG7-deleted skeletal muscle cells displayed defective respiration and increased generation of ROS. Aged spleens from senescence-accelerated prone mice revealed redox imbalance and age-related oxidative damage, as well as an upregulation of autophagy pathways believed to be a protective response to oxidative stress. It is also important to note that because autophagy initially plays a protective role against moderate oxidative stress, loss of autophagic function in aged cells is likely the reason why these cells have a lower tolerance to oxidative-induced injury.

The mechanism responsible for age-associated autophagic impairment is unknown, but the inability of lipofuscin-loaded secondary lysosomes to fuse with autophagosomes to form the autophagolysosome may contribute. Suppression of autophagy with 3-MA in an aged-cell model lipofuscin-loaded human fibroblasts significantly accelerated cell death. In addition, aged liver cells exhibit an accumulation of autophagosomes whose contents are unable to undergo final lysosomal degradation due to this impairment of lysosome/autophagosome fusion. Others suggest that changes in hormone levels and glucose metabolism that occur during aging may also play a role in the impairment of autophagy. Nevertheless, studies on aging in Drosophila, nematodes and rodents have shown that activation of autophagy likely prevents aging, while autophagic inhibition promotes the aging process.

This has led to investigators to explore potential methods of targeting autophagy to promote cell longevity. Spermidine, a naturally occurring polyamine that declines throughout a lifespan, inhibits oxidative stress and necrosis in aging yeast, and enhancing autophagy was essential for prevention of necrotic cell death. Because autophagy is strongly upregulated during periods of cell starvation and nutrient deprivation, it is believed that autophagy plays a key role in the anti-aging mechanism of caloric-restriction. Existing evidence supports this theory, as caloric-restriction has been shown to prevent age-dependent changes in cell membrane and hormone signaling and occur with an increase in autophagy.

(4) Autophagy and cancer. The function of autophagy in cancer is debatable with data supporting both a survival role and cancer suppressive role. Reduced autophagic activity is observed in tumor development, suggesting that perhaps autophagy is primarily a mechanism for tumor suppression. Additionally, oxidative stress and ROS-generation have been implicated in the pathogenesis of cancer, with cancerous cells generating higher levels of ROS than healthy cells. ROS accumulation overtime has been known to induce somatic mutations, and oxidative stress is directly associated with the development of prostate and chronic-inflammatory bowel disease-related colorectal cancer. The human oncosuppressor protein p53 promotes autophagy and reduces oxidative stress, suggesting that autophagy is exerting its tumor-suppressive actions in part by reducing levels of potentially mutagenic ROS. Another explanation for tumor-suppression by autophagy may be due to prolonged oxidative stress-induced autophagic cell death. H2O2 triggered autophagy-induced cell death in C6 glioma cells by BNIP3 inhibition of mTOR. ROS have been reported to induce autophagy in several cancer cell lines eventually resulting in cell death, while inhibition of autophagy with 3-MA or siRNA directed against ATGs inhibits this ROS-induced cell death. Allelic loss of beclin-1 is associated with human cancers that are susceptible to an accumulation of ROS and subsequent genomic damage and tumor growth. These findings give insight into the potential development of anti-cancer therapies that target autophagy for cancer prevention. For example, induction of oxidative stress by glucose oxidase or tert-butyl hydroperoxide induces autophagy and effectively suppresses tumor growth in a glioblastoma brain cancer model and HT-29 colon cancer cells respectively. Valproic acid, an anti-epileptic agent, was shown to also have tumor suppressing capabilities through an increase in ROS ERK1/2 dependent pathway that causes glioma cell death by autophagy. Interestingly, Δ9-tetrahydrocannabinol, the psychoactive compound found in marijuana, displays potential anti-tumor properties by inducing endoplasmic reticulum (ER)-stress and downstream inhibition of mTOR resulting in autophagic induced cell death. Autophagy induced by caloric restriction may prevent cancer, as caloric restriction has been reported to double the lifespan and delay tumor formation in mice. Pharmacologic agonists of autophagic pathways such as inhibitors of mTOR (i.e., rapamycin), and inhibitors targeting class I PI3K and 1,4,5-inositol triphosphate have been explored as potential chemotherapeutic agents. Additionally, chloroquine, an anti-malarial drug has been reported to prevent the development of lymphoma in mouse cancer models by activating autophagy.

Contrary to its role in the prevention of tumor development, it is also argued that autophagy plays a survival role in existing tumors because of its ability to cope with the hypoxic and nutrient-deprived environments found within tumors. Thus, agents used to induce autophagy as a preventative measure for tumor development may not be desirable in existing tumors where autophagy plays a critical role for their survival. Both thapsigargin, an ER-stress inducing agent, and rapamycin increased autophagy in multiple myeloma cell lines, while autophagic inhibition by 3-MA or beclin-1 siRNA resulted in cytotoxic effects and cell death. Evodiamine caused a time-dependent generation of ROS and triggered autophagy in human cervix carcinoma HeLa cells, while pre-treatment with 3-MA decreased cell viability, again indicating that autophagy is having a survival role in these cancer cells. This complexity and dual roles of autophagy in cancer suggests that both agonists and inhibitors of autophagy should be considered as potential anti-cancer therapies.

Targeting Autophagy as a Therapeutic Strategy Against Disease

Since manipulation of autophagic pathways can influence cell survival, targeting these pathways is an attractive therapeutic strategy against disease. As described in the previous sections,
inhibition or activation of autophagy at the genetic level with siRNA against essential autophagic genes or overexpression/constituent activation of these genes respectively, can affect cell viability. Common pharmacologic agents including 3-MA (an autophagic inhibitor) and rapamycin (autophagic activator) have been extensively utilized in laboratories to further characterize the role of autophagy in different cell systems. Additionally, the use of antioxidants such as NAC have also proved effective in preventing oxidative stress induced autophagy. In recent years, the development and exploration into novel pharmacologic therapies influencing autophagy has generated promising results against diseases, such as cancer, cardiovascular disease, neurological disorders, and age-related diseases. Refer to Table 2 for a summary of these drugs.

### References


### Summary

The autophagic process is highly regulated and is stimulated by several factors and has a multiplicity of functions. While basal levels of autophagy constantly function to maintain cell homeostasis in virtually every cell type, autophagic activity can be rapidly enhanced in response to elevated levels of ROS. However, whether this is a pro-survival response or one that contributes ultimately to cell death varies in different situations, and depends on the severity of oxidative stress occurring in a particular pathologic setting. Nevertheless, further exploration into the complex and diverse roles of ROS-mediated autophagy in different diseases, may reveal promising insights into pathogenic mechanisms, leading to novel therapeutic developments.

### Table 2. Drugs that influence autophagy in disease

<table>
<thead>
<tr>
<th>Drug</th>
<th>Disease</th>
<th>Action</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Everolimus</td>
<td>Atherosclerosis/myocardial</td>
<td>Induces autophagic cell death of macrophages in atherosclerotic arteries.</td>
<td>147, 148</td>
</tr>
<tr>
<td></td>
<td>infarction and pathologic</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>cardiac remodeling</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sulfaphenazole</td>
<td>Ischemia/reperfusion injury</td>
<td>Induces autophagy to reduce post-infarct remodeling, cardiac hypertrophy and improve function</td>
<td></td>
</tr>
<tr>
<td>Rotenone, Trifluoroacetone</td>
<td>Cancer</td>
<td>Electron transport chain inhibitors that cause ROS-mediated autophagic cell death and tumor suppression</td>
<td>37</td>
</tr>
<tr>
<td>Glucose oxidase, Tert-butyl hydroperoxide</td>
<td>Cancer</td>
<td>Tumor growth suppressed by ROS-mediated autophagy</td>
<td>129, 130</td>
</tr>
<tr>
<td>Valproic acid</td>
<td>Cancer</td>
<td>ROS-mediated autophagic cell death and tumor suppression</td>
<td>131</td>
</tr>
<tr>
<td>Bortezomib</td>
<td>Cancer (breast)</td>
<td>Inhibits pro-survival of autophagy in cancer cells, resulting in cell death</td>
<td>149</td>
</tr>
<tr>
<td>Δ1-tetrahydro-cannabinol</td>
<td>Cancer</td>
<td>Endoplasmic reticulum stress mediates autophagic cell death and tumor suppression</td>
<td>132</td>
</tr>
<tr>
<td>Chloroquine</td>
<td>Cancer (lymphoma)</td>
<td>Prevents cancer development by activation of autophagy</td>
<td>136</td>
</tr>
<tr>
<td>4-pyridyl-2-anilinothiazole, STF-62247</td>
<td>Cancer (renal cell carcinoma)</td>
<td>Prevents cancer development by activation of autophagy</td>
<td>150, 151</td>
</tr>
<tr>
<td>Indol-3-carbinol, genistin</td>
<td>Cancer (colon)</td>
<td>Prevents cancer development by activation of autophagy</td>
<td>152</td>
</tr>
<tr>
<td>Resveratrol</td>
<td>Aging Alzheimer</td>
<td>Prolongs lifespan by enhancing autophagy/autophagic degradation and clearance of amylod-beta aggregates in neuronal tissue</td>
<td>153, 154</td>
</tr>
<tr>
<td>Spermidine</td>
<td>Aging</td>
<td>Prolongs lifespan by enhancing autophagic cell repair and homeostasis</td>
<td>155</td>
</tr>
<tr>
<td>Acipimox</td>
<td>Aging</td>
<td>Prolongs lifespan by enhancing autophagic cell repair and homeostasis</td>
<td>156</td>
</tr>
</tbody>
</table>

**Table 2. Drugs that influence autophagy in disease**

174 Oxidative Medicine and Cellular Longevity Volume 3 Issue 3


113. Fu J, Shao CJ, Chen FR, Ng HK, Chen ZP. Autophagy induced by valproic acid is associated with oxidative stress in glioma cells. Neuro Oncol 2010; 12:328-40.


